Over the last five years we have followed the trials and tribulations of CAR T cell therapies in ALL and aggressive lymphomas as Novartis, Kite, Juno, Cellectis, Unum and others have undertaken the road less travelled towards filing and approval.
The ASH DASH in action!
Now that we have seen the first two CAR T cell approvals in pediatric ALL (Novartis) and aggressive lymphomas (Kite), with tisagenlecleucel widely expected to be the next one in aggressive lymphomas following presentation of the 6-month JULIET data at the recent American Society of Hematology (ASH) meeting in Atlanta, a key question remains to be addressed:
Is there a threat on the horizon that might be potentially used prior to CAR T cell therapy in refractory lymphomas?
We say ‘yes, there is’ and thus it was interesting to see where this approach might go… including discussion with an expert.
To learn more and get a heads up on our latest insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Atlanta – it’s day 2 of the annual meeting of the American Society of Hematology (ASH) meeting here in a chilly and snowy Atlanta.
I have to confess snow is not something we normally associate with southern States such as Georgia, but a cold snap has taken it’s toll on the ASH meeting, with many presentations cancelled as a result of travel delays.
Sunday at ASH is well known for the plenary session that takes place in the afternoon, but what else is hot at the meeting today? We’ve been talking to thought leaders, spending time in the vast poster hall and hearing some oral abstracts. There’s been been a surprising amount going on today at ASH in Atlanta.
If you are at ASH then you’ll know that all the sessions end at the same time, resulting in a massive movement of people as they go to the next session, as we saw today:
To get a heads up and further insights from ASH, subscribers can log-in or you can click to gain access to BSB Premium Content.